Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

High efficacy of blinatumomab combined with pembrolizumab in patients with relapsed/refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL): primary analysis of a Phase 1/2 study

Blood (2025) 146 (Supplement 1): 3352.

https://doi.org/10.1182/blood-2025-3352

Published: 2025

Journal Articles

Daunorubicin and cytarabine liposomal (CPX-351) plus glasdegib for newly diagnosed secondary Acute Myeloid Leukemia: Results of University of California hematologic malignancies consortium trial 1913

Deepa Jeyakumar, An To, Piyanuch Kongtim, Kiran Naqvi, Pamela Becker, Brian Jonas, Caspian Oliai, Gary Schiller, Matthew Wieduwilt, Lloyd Damon

Blood (2025) 146 (Supplement 1): 5241.

https://doi.org/10.1182/blood-2025-5241

Published: 2025

Journal Articles

Day 7 mount sinai acute GVHD international consortium (MAGIC) algorithm probability predicts GVHD and non-GVHD-related non-relapse mortality in a contemporary cohort of allogeneic transplant patients

Blood (2025) 146 (Supplement 1): 2464.

https://doi.org/10.1182/blood-2025-2464

Published: 2025

Journal Articles

The addition of venetoclax to FLAG IDA or FCE in relapsed or refractory (R/R) acute myeloid leukemia (AML)

Blood (2025) 146 (Supplement 1): 1684.

https://doi.org/10.1182/blood-2025-1684

Published: 2025

Journal Articles

Dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) yields durable remissions and survival in adults with newly diagnosed acute lymphoblastic leukemia/lymphoma (ALL): Long-term follow-up of a prospective trial

Mitin Nachu, Philip Stevenson, Kim Quach, Christen Martino, Mary-Elizabeth Percival, Anna Halpern, Pamela Becker, Vivian Oehler, Jason P. Cooper, Johnnie Orozco, Paul Hendrie, Roland Walter, Cristina Maria Ghiuzeli, Raya Mawad, Ryan Cassaday

Blood (2025) 146 (Supplement 1): 5128.

https://doi.org/10.1182/blood-2025-5128

Published: 2025

Journal Articles

Allogeneic hematopoietic stem cell transplantation for acute leukemias of mixed or ambiguous lineage

Blood (2025) 146 (Supplement 1): 4282.

https://doi.org/10.1182/blood-2025-4282

Published: 2025

Journal Articles

Prevalence and impact of somatic mutations in patients with aplastic anemia (AA) undergoing allogeneic hematopoietic cell transplantation (HCT): A single center retrospective analysis

Salman Otoukesh, Brian Ball, Dongyun Yang, Ketevan Gendzekhadze, Karamjeet Sandhu, Shukaib Arslan, Amanda Blackmon, Pamela Becker, Firoozeh Sahebi, Anna Pawlowska, Monzr M. Al Malki, Michelle Afkhami, Stephen Forman, Guido Marcucci, Vinod Pullarkat, Raju Pillai, Ryotaro Nakamura

Blood (2025) 146 (Supplement 1): 1431.

https://doi.org/10.1182/blood-2025-1431

Published: 2025

Journal Articles

Results of A phase I study of peposertib in combination with MEC in patients with relapsed or refractory Acute Myeloid Leukemia

Brian Jonas, Sangeetha Venugopal, George Yaghmour, Manu Pandey, Anthony Selwyn Stein, Mikkael Sekeres, Namrata Chandhok, Rasmus Hoeg, Joseph Tuscano, Pamela Becker, Terrence Bradley, Eric Tam, Guido Marcucci, Paul Frankel, Jan Beumer, Steven Gore, Alexey Danilov, Amandeep Salhotra

Blood (2025) 146 (Supplement 1): 1651.

https://doi.org/10.1182/blood-2025-1651

Published: 2025

Journal Articles

A functional precision medicine clinical trial in Relapsed/Refractory multiple myeloma: Prospective study of a high throughput drug sensitivity assay on correlation of drug sensitivity scores with treatment response

Raffaella Cassano Cassano, Timothy Martins, David Coffey, Gabriele Buda, Sara Galimberti, Ryan Donnelly, Mary Kwok, Damian Green, Rahul Banerjee, Kara Cicero, Ted Gooley, Rebecca Silbermann, Pamela Becker, Andrew Cowan

Blood (2025) 146 (Supplement 1): 7446.

https://doi.org/10.1182/blood-2025-7446

Published: 2025

Journal Articles

The transition from myelodysplastic neoplasm to secondary acute myeloid leukemia is revealed by molecular analysis, while functional drug screening demonstrates novel sensitivity patterns with clinical implication

Blood (2025) 146 (Supplement 1): 4328.

https://doi.org/10.1182/blood-2025-4328

Published: 2025

Journal Articles

Clearance of RAS pathway mutations prior to allogeneic transplant in Acute Myeloid Leukemia are associated with favorable overall and leukemia free survival

Blood (2025) 146 (Supplement 1): 4305.

https://doi.org/10.1182/blood-2025-4305

Published: 2025

Journal Articles

Update from an Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Romiplostim In Thrombocytopenic Patients (Pts) with Myelodysplastic Syndromes (MDS)

Pierre Fenaux, MD, PhD, Hagop Kantarjian, MD, Roger M Lyons, MD, Richard A Larson, MD, Mikkael A Sekeres, MD, MS, Pamela Becker, MD, PhD, Petra Muus, MD, PhD, Catherine Jia, PhD, Allen S Yang, MD, PhD

Blood (2010) 116 (21): 1885.

https://doi.org/10.1182/blood.V116.21.1885.1885

Published: 2010

Journal Articles

A Phase II Study of Bortezomib (Velcade ® ), Cyclophosphamide (Cytoxan ® ), Thalidomide (Thalomid ® ) and Dexamethasone as First-Line Therapy for Multiple Myeloma

William Bensinger, Sundar Jagannath, MD, Robert Vescio, MD, Elber S. Camacho, MD, Jeffrey Lee Wolf, David H Irwin, MD, Gerardo Capo, III, MD, Marti McKinley, Phyllis Potts, David H. Vesole, MD, PhD, Amitabha Mazumder, MD, Dixie-Lee Esseltine, MD, Pamela Becker, John Crowley, PhD, Brian GM Durie, MD

Blood (2008) 112 (11): 94.

https://doi.org/10.1182/blood.V112.11.94.94

Published: 2008

Journal Articles

Phase 1/2 Study of AMG 531 in Thrombocytopenic Patients (pts) with Low-Risk Myelodysplastic Syndrome (MDS): Update Including Extended Treatment.

Hagop Kantarjian, Pierre Fenaux, Mikkael A. Sekeres, Pamela Becker, Adam Boruchov, David Bowen, Richard Larson, Roger Lyons, Petra Muus, Jamile Shammo, Michael Ehrman, Kuolung Hu, Janet Nichol

Blood (2007) 110 (11): 250.

https://doi.org/10.1182/blood.V110.11.250.250

Published: 2007

Journal Articles

Favorable Outcomes with Acceptable Toxicity Using a Reduced Intensity Conditioning Regimen for Patients Otherwise Ineligible for Related Donor Allogeneic Stem Cell Transplantation.

Peter Westervelt, MD, PhD, Wendy Holmes, RN, PhD, Robert Emmons, MD, Pamela Becker, MD, PhD, Phil Lowry, MD, Ann Traynor, MD, Karen Ballen, MD

Blood (2004) 104 (11): 5137.

https://doi.org/10.1182/blood.V104.11.5137.5137

Published: 2004

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

High efficacy of blinatumomab combined with pembrolizumab in patients with relapsed/refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL): primary analysis of a Phase 1/2 study

Daunorubicin and cytarabine liposomal (CPX-351) plus glasdegib for newly diagnosed secondary Acute Myeloid Leukemia: Results of University of California hematologic malignancies consortium trial 1913

Day 7 mount sinai acute GVHD international consortium (MAGIC) algorithm probability predicts GVHD and non-GVHD-related non-relapse mortality in a contemporary cohort of allogeneic transplant patients

The addition of venetoclax to FLAG IDA or FCE in relapsed or refractory (R/R) acute myeloid leukemia (AML)

Dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) yields durable remissions and survival in adults with newly diagnosed acute lymphoblastic leukemia/lymphoma (ALL): Long-term follow-up of a prospective trial

Allogeneic hematopoietic stem cell transplantation for acute leukemias of mixed or ambiguous lineage

Prevalence and impact of somatic mutations in patients with aplastic anemia (AA) undergoing allogeneic hematopoietic cell transplantation (HCT): A single center retrospective analysis

Results of A phase I study of peposertib in combination with MEC in patients with relapsed or refractory Acute Myeloid Leukemia

A functional precision medicine clinical trial in Relapsed/Refractory multiple myeloma: Prospective study of a high throughput drug sensitivity assay on correlation of drug sensitivity scores with treatment response

The transition from myelodysplastic neoplasm to secondary acute myeloid leukemia is revealed by molecular analysis, while functional drug screening demonstrates novel sensitivity patterns with clinical implication

Clearance of RAS pathway mutations prior to allogeneic transplant in Acute Myeloid Leukemia are associated with favorable overall and leukemia free survival

Update from an Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Romiplostim In Thrombocytopenic Patients (Pts) with Myelodysplastic Syndromes (MDS)

A Phase II Study of Bortezomib (Velcade ® ), Cyclophosphamide (Cytoxan ® ), Thalidomide (Thalomid ® ) and Dexamethasone as First-Line Therapy for Multiple Myeloma

Phase 1/2 Study of AMG 531 in Thrombocytopenic Patients (pts) with Low-Risk Myelodysplastic Syndrome (MDS): Update Including Extended Treatment.

Favorable Outcomes with Acceptable Toxicity Using a Reduced Intensity Conditioning Regimen for Patients Otherwise Ineligible for Related Donor Allogeneic Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only